Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Research Determines Why Different Cancers Display Similar Profiles

By LabMedica International staff writers
Posted on 17 Oct 2018
A team of cancer researchers has identified a molecular mechanism that may explain why gene expression profiles are similar in late stage cancers from different organs.

The use of modern chemotherapeutic techniques to treat epithelial cancers leads to the development of multiple resistance mechanisms, including the generation of highly aggressive, small cell neuroendocrine carcinoma (SCNC). More...
SCNC patients have a poor prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. In particular, whether distinct cancer types accomplish this “reprogramming” through the same mechanism has been unclear.

Investigators at the University of California, Los Angeles (USA) reported in the October 5, 2018, issue of the journal Science that while healthy prostate and lung cells have very different patterns of gene expression, they display almost identical patterns when they transform into small cell cancers.

The investigators found that a common set of defined oncogenic drivers reproducibly reprogrammed normal human prostate and lung epithelial cells and transformed them into small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. They identified shared active transcription factor binding regions in the reprogrammed prostate and lung SCNCs by integrative analyses of epigenetic and transcriptional landscapes.

"Small cell cancers of the lung, prostate, bladder, and other tissues were long thought to be similar in name alone - and they were treated by oncologists as different entities," said senior author Dr. Owen Witte, professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles. "Over the past few years, though, researchers have increasingly begun to realize that there are similarities in the cancers, and that's what our work confirms. Our study revealed shared "master gene regulators" - the key proteins that control expression of multiple genes in small cell cancer cells. Studying the network of the master gene regulators could lead to a new way of combating deadly cancers."

Overall, the results presented in this study suggest that neuroendocrine cancers arising from distinct epithelial tissues may share common vulnerabilities that could be exploited for the development of new drugs to treat SCNCs.

Related Links:
University of California, Los Angeles


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.